SystImmune Inc.
SystImmune is a biopharmaceutical company focused on the development of novel bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for the treatment of cancer. Our goal is to create biologics that directly attack tumors, intervene in tumor microenvironments, and activate the immune system against tumors. We have eight in-house developed assets in clinical testing. SystImmune is committed to driving systematic intervention in oncology using clinical and preclinical sciences, to achieve therapeutic impact for patients and their families. https://systimmune.com